



TALKMED GROUP LIMITED
(Company Registration No. 201324565Z)

CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2023

A. Condensed interim consolidated statement of profit or loss and other comprehensive income

	Note	6 months ended 30 June 2023 ("1H 2023") \$'000 (Unaudited)	6 months ended 30 June 2022 ("1H 2022") \$'000 (Unaudited)	Increase / (Decrease) %
The Group				
Revenue	4	37,795	32,469	16.4%
Other items of income				
Interest income		991	148	569.6%
Other income		103	177	(41.8%)
Other items of expense				
Employee benefits expense		(15,316)	(13,361)	14.6%
Share-based payments expense		(274)	(261)	5.0%
Operating lease expense		(34)	(31)	9.7%
Depreciation of right-of-use assets		(1,049)	(1,011)	3.8%
Depreciation of property, plant and equipment		(317)	(267)	18.7%
Finance costs		(157)	(182)	(13.7%)
Other operating expenses		(3,872)	(2,196)	76.3%
Impairment loss		(454)	–	N.M.
Share of results of associate		(18)	(78)	(76.9%)
Share of results of joint ventures		(985)	(791)	24.5%
Profit before tax	6	16,413	14,616	12.3%
Income tax expense	7	(3,924)	(3,167)	23.9%
Profit for the period		12,489	11,449	9.1%

N.M. = not meaningful

A. Condensed interim consolidated statement of profit or loss and other comprehensive income (cont'd)

The Group	1H 2023 \$'000 (Unaudited)	1H 2022 \$'000 (Unaudited)	Increase / (Decrease) %
Attributable to:			
Owners of the Company	14,272	12,130	17.7%
Non-controlling interests	(1,783)	(681)	161.8%
	12,489	11,449	9.1%
Other comprehensive income:			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation	(52)	(34)	52.9%
Other comprehensive income for the period, net of tax	(52)	(34)	52.9%
Total comprehensive income for the period	12,437	11,415	9.0%
Attributable to:			
Owners of the Company	14,220	12,096	17.6%
Non-controlling interests	(1,783)	(681)	161.8%
Total comprehensive income for the period	12,437	11,415	9.0%

B. Condensed interim statements of financial position

	Note	Group		Company	
		30/06/2023 \$'000 (Unaudited)	31/12/2022 \$'000 (Audited)	30/06/2023 \$'000 (Unaudited)	31/12/2022 \$'000 (Audited)
ASSETS					
Non-current assets					
Property, plant and equipment	11	6,090	5,999	–	–
Right-of-use assets		4,187	4,083	–	–
Investment property	15	–	–	3,936	4,007
Investment in subsidiaries	12	–	–	19,991	19,152
Investment in joint ventures	16	801	1,786	–	–
Investment in associate		1,892	1,910	11,399	11,399
Loan to a joint venture	16	–	306	–	–
Trade receivables		376	300	–	–
		13,346	14,384	35,326	34,558
Current assets					
Inventories		1,208	1,275	–	–
Prepaid operating expenses		311	444	13	20
Trade and other receivables		9,323	11,822	2,031	459
Investment securities held for sale	14	514	653	514	653
Cash and short-term deposits		81,074	80,588	60,167	22,618
		92,430	94,782	62,725	23,750
Total assets		105,776	109,166	98,051	58,308
EQUITY AND LIABILITIES					
Current liabilities					
Trade and other payables		4,538	2,867	53	66
Other liabilities		8,762	6,815	33	181
Lease liabilities		1,876	1,851	–	–
Income tax payable		7,847	7,850	–	–
		23,023	19,383	86	247
Net current assets		69,407	75,399	62,639	23,503
Non-current liabilities					
Lease liabilities		2,619	2,552	–	–
Loan from non-controlling shareholder to a subsidiary		2,741	2,682	–	–
		5,360	5,234	–	–
Total liabilities		28,383	24,617	86	247
Net assets		77,393	84,549	97,965	58,061

B. Condensed interim statements of financial position (cont'd)

	Note	Group		Company	
		30/06/2023	31/12/2022	30/06/2023	31/12/2022
		\$'000 (Unaudited)	\$'000 (Audited)	\$'000 (Unaudited)	\$'000 (Audited)
Equity attributable to owners of the Company					
Share capital	13	25,572	25,119	25,572	25,119
Merger reserve		(2,311)	(2,311)	–	–
Share-based payments reserve		549	930	549	930
Other reserve		2,807	2,807	–	–
Foreign currency translation reserve		(200)	(148)	–	–
Retained earnings		56,889	62,317	71,844	32,012
		83,306	88,714	97,965	58,061
Non-controlling interests		(5,913)	(4,165)	–	–
Total equity		77,393	84,549	97,965	58,061
Total equity and liabilities		105,776	109,166	98,051	58,308

C. Condensed interim statements of changes in equity

The Group (Unaudited)	Note	Attributable to owners of the Company							Total equity \$'000
		Share capital \$'000	Merger reserve \$'000	Share- based payments reserve \$'000	Other reserve \$'000	Foreign currency translation reserve \$'000	Retained earnings \$'000	Non- controlling interests \$'000	
Balance at 1 January 2023		25,119	(2,311)	930	2,807	(148)	62,317	(4,165)	84,549
Profit for the period		–	–	–	–	–	14,272	(1,783)	12,489
<u>Other comprehensive income</u>									
Foreign currency translation		–	–	–	–	(52)	–	–	(52)
Other comprehensive income for the period, net of tax		–	–	–	–	(52)	–	–	(52)
Total comprehensive income for the period		–	–	–	–	(52)	14,272	(1,783)	12,437
<u>Distributions to and contributions by owners</u>									
Dividends	8	–	–	–	–	–	(19,867)	–	(19,867)
Share-based payments		–	–	239	–	–	–	35	274
Lapsed employee share options		–	–	(167)	–	–	167	–	–
Ordinary shares issued upon vesting of performance shares	13	453	–	(453)	–	–	–	–	–
Balance at 30 June 2023		25,572	(2,311)	549	2,807	(200)	56,889	(5,913)	77,393

C. Condensed interim statements of changes in equity (cont'd)

The Group (Unaudited)	Note	Attributable to owners of the Company							Total equity \$'000
		Share capital \$'000	Merger reserve \$'000	Share- based payments reserve \$'000	Other reserve \$'000	Foreign currency translation reserve \$'000	Retained earnings \$'000	Non- controlling interests \$'000	
Balance at 1 January 2022		24,505	(2,311)	1,446	2,807	564	63,167	(2,678)	87,500
Profit for the period		–	–	–	–	–	12,130	(681)	11,449
<u>Other comprehensive income</u>									
Foreign currency translation		–	–	–	–	(34)	–	–	(34)
Other comprehensive income for the period, net of tax		–	–	–	–	(34)	–	–	(34)
Total comprehensive income for the period		–	–	–	–	(34)	12,130	(681)	11,415
<u>Distributions to and contributions by owners</u>									
Dividends	8	–	–	–	–	–	(11,898)	–	(11,898)
Share-based payments		–	–	225	–	–	–	36	261
Lapsed employee share options		–	–	(332)	–	–	332	–	–
Ordinary shares issued upon vesting of performance shares		492	–	(492)	–	–	–	–	–
Balance at 30 June 2022		24,997	(2,311)	847	2,807	530	63,731	(3,323)	87,278

C. Condensed interim statements of changes in equity (cont'd)

The Company (Unaudited)	Note	Attributable to owners of the Company			
		Share capital \$'000	Share-based payments reserve \$'000	Retained earnings \$'000	Total equity \$'000
Balance at 1 January 2023		25,119	930	32,012	58,061
Profit for the period, representing total comprehensive income for the period		–	–	59,532	59,532
<u>Distributions to and contributions by owners</u>					
Dividends	8	–	–	(19,867)	(19,867)
Share-based payments		–	239	–	239
Ordinary shares issued upon vesting of performance shares	13	453	(453)	–	–
Lapsed employee share options		–	(167)	167	–
Balance at 30 June 2023		25,572	549	71,844	97,965
Balance at 1 January 2022		24,505	1,446	21,718	47,669
Profit for the period, representing total comprehensive income for the period		–	–	11,461	11,461
<u>Distributions to and contributions by owners</u>					
Dividends	8	–	–	(11,898)	(11,898)
Share-based payments		–	225	–	225
Ordinary shares issued upon vesting of performance shares		492	(492)	–	–
Lapsed employee share options		–	(332)	332	–
Balance at 30 June 2022		24,997	847	21,613	47,457

D. Condensed interim consolidated statement of cash flows

The Group	Note	1H 2023 \$'000 (Unaudited)	1H 2022 \$'000 (Unaudited)
Operating Activities			
Profit before tax		16,413	14,616
<u>Adjustments for:</u>			
Depreciation of property, plant and equipment		317	267
Depreciation of right-of-use assets		1,049	1,011
Share-based payments expense		274	261
Finance costs on unwinding of discount adjustment of loan to a subsidiary	6	59	68
Finance costs on lease liabilities	6	98	114
Interest income		(991)	(148)
Impairment loss on loan granted to a joint venture	16	315	–
Impairment loss on investment securities held for sale	14	139	–
Share of results of associate		18	78
Share of results of joint ventures		985	791
Currency re-alignment		(9)	5
Operating cash flows before changes in working capital		18,667	17,063
Changes in working capital			
Decrease/(increase) in inventories		67	(155)
Decrease in prepaid operating expenses		133	31
Decrease in trade and other receivables		2,423	388
Increase in trade and other payables		1,671	83
Increase in other liabilities		1,947	40
Total changes in working capital		6,241	387
Cash flows generated from operations		24,908	17,450
Interest received		982	182
Interest paid on lease liabilities		(98)	(114)
Income tax paid		(3,927)	(2,944)
Net cash flows generated from operating activities		21,865	14,574
Investing Activities			
Purchase of property, plant and equipment	11	(451)	(23)
Investment in joint venture	16	–	(86)
Net cash flows used in investing activities		(451)	(109)
Financing Activities			
Dividends paid on ordinary shares	8	(19,867) ⁽¹⁾	(11,898) ⁽²⁾
Payment for principal portion of lease liabilities		(1,061)	(985)
Net cash flows used in financing activities		(20,928)	(12,883)
Net increase in cash and cash equivalents		486	1,582
Cash and cash equivalents at beginning of the period		80,588	82,164
Cash and cash equivalents at end of the period		81,074	83,746

E. Notes to the condensed interim consolidated financial statements

1. Corporate information

TalkMed Group Limited (the “**Company**”) is a limited liability company incorporated and domiciled in Singapore and is listed on the Singapore Exchange Securities Trading Limited (“**SGX-ST**”). The immediate and ultimate holding company is Ladyhill Holdings Pte. Ltd. which is incorporated in Singapore.

The registered office of the Company is at 101 Thomson Road, #09-02 United Square, Singapore 307591 and the principal place of business of the Group is at 3 Mount Elizabeth, Mount Elizabeth Hospital Level 2, Singapore 228510.

The principal activity of the Company is that of investment holding. The principal activities of the subsidiaries, joint ventures and associate are:

- (a) Provision of specialist doctors and medical staff to operate Parkway Cancer Centre which is a division of Parkway Hospitals Singapore Pte. Ltd. for specialist oncology services;
- (b) Provision of specialised medical oncology services;
- (c) Provision of healthcare management services;
- (d) Provision of cellular and gene therapy related products and services; and
- (e) Provision of services to establish internet hospitals and to operate internet pharmacies.

These condensed interim consolidated financial statements as at and for the six months ended 30 June 2023 (“**1H 2023**”) comprise the Company and its subsidiaries (collectively, the “**Group**”).

2. Basis of preparation

The condensed interim financial statements for 1H 2023 have been prepared in accordance with Singapore Financial Reporting Standard (International) (“**SFRS(I)**”) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last annual financial statements for the year ended 31 December 2022.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore dollars (“**\$**”) which is the Company’s functional currency and all values are rounded to the nearest thousand (“**\$’000**”) as indicated.

2.1 New and amended standards adopted by the Group

A number of amendments to SFRS(I)s have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

There were no significant judgements made by management in applying the Group’s accounting policies for the condensed interim financial statements. The key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2022.

2. Basis of preparation (cont'd)

2.2 Use of judgements and estimates (cont'd)

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following note:

- Note 12 – impairment assessment of investment in subsidiary and loan to subsidiary: key assumptions underlying recoverable amounts
- Note 16 – impairment assessment of loan to a joint venture: key assumptions underlying recoverable amount

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segment and revenue information

For management purposes, the Group is organised into business units based on their products and services, and has two reportable operating segments as follows:

i) Oncology services

Consultancy services

The Group provides specialist doctors and clinical staff to Parkway Cancer Centre ("**PCC**"), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services ("**consultancy services**"). Revenue from the provision of such consultancy services to PCC is recognised when the services are rendered and is computed in accordance with the terms and conditions of the Consultancy Restatement Agreement.

The Group provides consultancy services to Thu Cuc International General Hospital ("**TCH**"), to enable TCH to operate a medical centre for the provision of oncology services in Hanoi, Vietnam. Revenue from the provision of such consultancy services to TCH is recognised when the services are rendered and is computed in accordance with the terms and conditions of the profit-sharing agreement.

The Group provides consultancy services to its associate, Hong Kong Integrated Oncology Centre Holdings Limited ("**HKH**") for a fixed annual fee. Revenue from the provision of such consultancy services to HKH is recognised when the services are rendered.

The Group provides consultancy services to patients in Beijing and Chongqing, the People's Republic of China, through TalkMed Shanshui Medical Centre ("**TSMC**") and Sino-Singapore Cancer Centre ("**SSCC**") respectively. The business operations of TSMC and SSCC commenced in the first-half of 2021.

4. Segment and revenue information (cont'd)

i) Oncology services (cont'd)

Management fees

Revenue from management fees is derived from the billing of salaries, wages and employee benefits and rental of premises incurred by Singapore Cancer Centre Pte. Ltd. ("**SCC**") from the provision of its specialist medical oncology services by SCC's employees and specialist doctors to PCC and all expenses incurred from the provision of consultancy services by SCC's specialist doctors to TCH. Revenue from management fees is recognised when the services are rendered.

ii) Cellular and gene therapy related products and services

The provision of goods and services related to cellular and gene therapy is through its subsidiary, CellVec Pte. Ltd. ("**CellVec**"). Revenue from the manufacturing of cellular and gene therapy related products is recognised at the point in time when control of the products is transferred to the customer, generally on delivery of the products to the customer and when all criteria for acceptance have been satisfied. Revenue from the provision of cellular and gene therapy related services is recognised over time as the customers simultaneously receive the benefits as it performs the services.

4.1 Reportable segments

	Group		
	Oncology services \$'000 (Unaudited)	Cellular and gene therapy related products and services \$'000 (Unaudited)	Per consolidated financial statements \$'000 (Unaudited)
1 January to 30 June 2023			
Revenue			
External customers, representing total revenue	37,478	317	37,795
Results			
Interest income	991	–	991
Employee benefits expense	13,373	1,943	15,316
Share-based payments expense	274	–	274
Depreciation of right-of-use assets	885	164	1,049
Depreciation of property, plant and equipment	293	24	317
Finance costs on lease liabilities	75	23	98
Finance costs on unwinding of discount adjustment of loan to a subsidiary	–	59	59
Impairment loss	454	–	454
Share of results of associate	18	–	18
Share of results of joint ventures	985	–	985
Income tax expense	3,924	–	3,924
Segment profit/(loss)	16,858	(4,369)	12,489
Assets			
Investment in associate	1,892	–	1,892
Investment in joint ventures	801	–	801
Investment securities held for sale	514	–	514
Segment assets	97,069	5,500	102,569
Total assets	100,276	5,500	105,776
Liabilities			
Segment liabilities	18,284	10,099	28,383

4. Segment and revenue information (cont'd)

4.1 Reportable segments (cont'd)

	Group		
	Oncology services \$'000 (Unaudited)	Cellular and gene therapy related products and services \$'000 (Unaudited)	Per consolidated financial statements \$'000 (Unaudited)
1 January to 30 June 2022			
Revenue			
External customers, representing total revenue	31,259	1,210	32,469
Results			
Interest income	148	–	148
Employee benefits expense	11,931	1,430	13,361
Share-based payments expense	261	–	261
Depreciation of right-of-use assets	882	129	1,011
Depreciation of property, plant and equipment	266	1	267
Finance costs on lease liabilities	105	9	114
Finance costs on unwinding of discount adjustment of loan to a subsidiary	–	68	68
Share of results of associate	78	–	78
Share of results of joint ventures	791	–	791
Income tax expense	3,167	–	3,167
Segment profit/(loss)	13,049	(1,600)	11,449
Assets			
Investment in associate	2,164	–	2,164
Investment in joint ventures	3,397	–	3,397
Investment securities held for sale	1,093	–	1,093
Segment assets	96,904	4,466	101,370
Total assets	103,558	4,466	108,024
Liabilities			
Segment liabilities	16,010	4,736	20,746

4. Segment and revenue information (cont'd)

4.2 Disaggregation of revenue

The table below summarises information about the Group's revenues for 1H 2023 and 1H 2022 which are disaggregated by segments, geographical markets and the timing of transfer of goods or services (either at a point in time or over time).

	Group							
	Oncology services				Cellular and gene therapy related products and services		Total revenue	
	Consultancy services		Management fees					
	1H 2023	1H 2022	1H 2023	1H 2022	1H 2023	1H 2022	1H 2023	1H 2022
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Primary geographical markets								
Singapore	26,591	20,981	10,063	9,916	–	–	36,654	30,897
China and Hong Kong	703	256	75	66	–	–	778	322
Vietnam	32	31	14	9	–	–	46	40
Australia	–	–	–	–	12	788	12	788
India	–	–	–	–	–	417	–	417
Others	–	–	–	–	305	5	305	5
	27,326	21,268	10,152	9,991	317	1,210	37,795	32,469
Timing of transfer of goods or services								
At a point in time	–	–	–	–	317	1,210	317	1,210
Over time	27,326	21,268	10,152	9,991	–	–	37,478	31,259
	27,326	21,268	10,152	9,991	317	1,210	37,795	32,469

5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 June 2023 and 31 December 2022:

	Group		Company	
	30/06/2023 \$'000 (Unaudited)	31/12/2022 \$'000 (Audited)	30/06/2023 \$'000 (Unaudited)	31/12/2022 \$'000 (Audited)
Financial assets				
Trade and other receivables (current)	9,323	11,822	2,031	459
Trade receivables (non-current)	376	300	–	–
Loan to a joint venture	–	306	–	–
Cash and short-term deposits	81,074	80,588	60,167	22,618
Less: GST receivable	(361)	(360)	(283)	(283)
Total financial assets carried at amortised cost	90,412	92,656	61,915	22,794
Financial liabilities				
Trade and other payables	4,538	2,867	53	66
Accrued operating expenses	4,252	4,684	33	181
Lease liabilities	4,495	4,403	–	–
Loan from non-controlling shareholder to a subsidiary	2,741	2,682	–	–
Less: GST payable	(1,486)	(1,361)	–	–
Total financial liabilities carried at amortised cost	14,540	13,275	86	247

6. Profit before tax

6.1 Significant items

	Group	
	1H 2023 \$'000 (Unaudited)	1H 2022 \$'000 (Unaudited)
Finance costs on:		
- Lease liabilities	98	114
- Unwinding of discount adjustment of loan to a subsidiary	59	68
	157	182

6. Profit before tax (cont'd)

6.2 Related party transactions

(a) Sales and purchases of goods and services

In addition to the related party information disclosed elsewhere in this set of condensed interim financial statements, the following significant transactions between the Group and related parties took place at terms agreed between the parties during 1H 2023 and 1H 2022:

	Group	
	1H 2023	1H 2022
	\$'000	\$'000
	(Unaudited)	(Unaudited)
Lease payments to directors and director-related companies	564	564
Lease payments to non-controlling shareholder	83	83
Service fees paid to director-related companies	–	4
Payments made on behalf by non-controlling shareholder	1	–
Consultancy services rendered to associate	88	135
	<hr/>	<hr/>

(b) Compensation of key management personnel

	Group	
	1H 2023	1H 2022
	\$'000	\$'000
	(Unaudited)	(Unaudited)
Short-term employee benefits	3,508	3,516
Directors' fees – directors of the Company and subsidiaries	250	250
Central Provident Fund contributions	35	34
Share-based payments expense	32	31
	<hr/>	<hr/>
	3,825	3,831
	<hr/>	<hr/>
Comprised amounts paid/payable to:		
- Directors of the Company	2,967	2,959
- Other key management personnel	858	872
	<hr/>	<hr/>
	3,825	3,831
	<hr/>	<hr/>

7. Taxation

The Group calculates the income tax expense for 1H 2023 and 1H 2022 using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	Group	
	1H 2023	1H 2022
	\$'000	\$'000
	(Unaudited)	(Unaudited)
Current income tax:		
- Current income taxation	3,924	3,167
	<hr/>	<hr/>
Income tax expense recognised in profit or loss	3,924	3,167
	<hr/> <hr/>	<hr/> <hr/>

8. Dividends

	Group and Company	
	1H 2023	1H 2022
	\$'000	\$'000
	(Unaudited)	(Unaudited)
Declared and paid:		
<i>Dividends on ordinary shares:</i>		
- Final exempt (one-tier) dividend for 2022: 1.50 cents (2021: 0.90 cents) per share	19,867 ⁽¹⁾	11,898 ⁽²⁾
Declared but not paid:		
- First interim exempt (one-tier) dividend for 2023: 0.90 cents (2022: 1.50 cents) per share	11,920	19,831
	<hr/>	<hr/>
	31,787	31,729
	<hr/> <hr/>	<hr/> <hr/>

⁽¹⁾ The final dividend paid to shareholders and the proposed final dividend (as previously disclosed in the full year announcement for the year ended 31 December 2022) were \$19,867,000 and \$19,838,000 respectively. The difference of approximately \$29,000 between the final dividend paid and the proposed final dividend to be paid to shareholders for 2022 arose due to the dividends paid on 1,945,210 ordinary shares issued on 13 March 2023. 1,945,210 ordinary shares were allotted and issued on 13 March 2023 pursuant to the vesting of certain performance shares awarded to employees of the Group in March 2020. These newly allotted ordinary shares were eligible for the final dividend which was paid on 11 May 2023.

⁽²⁾ The final dividend paid to shareholders and the proposed final dividend (as previously disclosed in the full year announcement for the year ended 31 December 2021) were \$11,898,000 and \$11,881,000 respectively. The difference of approximately \$17,000 between the final dividend paid and the proposed final dividend to be paid to shareholders for 2021 arose due to the dividends paid on 1,945,209 ordinary shares issued on 14 March 2022. 1,945,209 ordinary shares were allotted and issued on 14 March 2022 pursuant to the vesting of certain performance shares awarded to employees of the Group in March 2020. These newly allotted ordinary shares were eligible for the final dividend which was paid on 11 May 2022.

9. Earnings per share

The Group	1H 2023 (Unaudited)	1H 2022 (Unaudited)
Profit attributable to owners of the Company (\$'000)	14,272	12,130
Weighted average number of ordinary shares used in the computation of basic earnings per share	1,323,736,727	1,321,280,771
Basic earnings per share (cents)	1.08	0.92
Weighted average number of ordinary shares used in the computation of diluted earnings per share	1,331,553,501	1,328,956,501
Diluted earnings per share (cents)	1.07	0.91

10. Net asset value

	Group		Company	
	30/06/2023 (Unaudited)	31/12/2022 (Audited)	30/06/2023 (Unaudited)	31/12/2022 (Audited)
Net asset value attributable to owners of the Company (\$'000)	83,306	88,714	97,965	58,061
Net asset value per ordinary share at end of the financial period (cents)	6.29 ⁽¹⁾	6.71 ⁽²⁾	7.40 ⁽¹⁾	4.39 ⁽²⁾

⁽¹⁾The calculation of net asset value per ordinary share was based on 1,324,499,765 shares as at 30 June 2023.

⁽²⁾The calculation of net asset value per ordinary share was based on 1,322,554,555 shares as at 31 December 2022.

11. Property, plant and equipment

During 1H 2023, the Group acquired assets amounting to \$451,000 (1H 2022: \$23,000). There was no disposal of assets during 1H 2023 and 1H 2022.

12. Investment in subsidiaries

	Company	
	30/06/2023 \$'000 (Unaudited)	31/12/2022 \$'000 (Audited)
Equity shares, at cost	23,610	23,010
Discount on interest-free loan to a subsidiary	960	960
Deemed contribution in respect of share-based payments to employees of Singapore Cancer Centre Pte. Ltd. ("SCC")	4,347	4,108
Impairment losses	(8,926)	(8,926)
	<u>19,991</u>	<u>19,152</u>

As at 30 June 2023, the Company's cost of investment in subsidiaries amounted to \$23,610,000 (2022: \$23,010,000). The increase in the cost of investment in subsidiaries was due to additional capital injection of \$600,000 in its subsidiary, TalkMed Greater China Pte. Ltd..

During 1H 2023, the Company carried out an impairment review following which no reversal of impairment loss was made on the carrying amount of the Company's investment in CellVec as the estimated value-in-use is negative.

12. Investment in subsidiaries (cont'd)

For the financial year ended 31 December 2022, due to the continued losses incurred by the cellular and gene therapy segment, the Company recognised additional impairment loss of \$1,800,000 which represented a full impairment on the carrying value of the Company's investment in CellVec as the estimated value-in-use based on the impairment assessment was negative.

Impairment test for investment in CellVec, including loan to CellVec

	Carrying amount		Basis on which recoverable amount is determined	Post-tax discount rate per annum	
	30/06/2023	31/12/2022		30/06/2023	31/12/2022
	\$'000 (Unaudited)	\$'000 (Audited)			
Group					
CellVec					
Property, plant and equipment	838	411	Value-in-use	27.2%	27.7%
Company					
CellVec					
Investment in subsidiary	–	–	Value-in-use	27.2%	27.7%
Loan to subsidiary	–	–	Value-in-use	27.2%	27.7%

CellVec provides cellular and gene therapy related products and services. The recoverable amounts of the investment in CellVec and loan to CellVec, and its property, plant and equipment have been determined based on value-in-use calculation using cash flow projections from financial budgets that were approved by management. For purpose of determining the value-in-use of the investment in CellVec, the cash flows beyond the initial five years were extrapolated using a long-term growth rate of 2.0% (2022: 2.0%) which was determined based on market information consistent for the industry it operates in. The cash flows for the initial five years included revenue growth rate of between 5% and 97% (2022: 5% and 122%).

Based on the impairment review carried out during 1H 2023, the Company recognised impairment losses of \$89,000 in respect of the interest income on unwinding of the discount adjustment of the Company's loan to CellVec. No reversal has been made in respect of the impairment losses previously recognised on the Company's investment in CellVec and loan to CellVec, and the Group's property, plant and equipment.

For the financial year ended 31 December 2022, the Company recognised impairment losses of \$1,800,000 and \$204,000 in respect of the carrying amount of the Company's additional investments in CellVec and loan to CellVec respectively. The impairment losses represented the shortfall between the estimated value-in-use and carrying amounts of the Company's investment in CellVec and loan to CellVec.

Key assumptions used in the value-in-use calculations

Growth rates – The forecasted growth rates are based on published industry research and are comparable to the average growth rate for the industry relevant to the entity.

Post-tax discount rate – Discount rate represents the current market assessment of the risks specific to the entity, regarding the time value of money and individual risks of the underlying assets which have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Group and its operating segments and derived from its weighted average cost of capital.

12. Investment in subsidiaries (cont'd)

Impairment test for investment in CellVec, including loan to CellVec (cont'd)

Summary of sensitivity to changes in assumptions

Management is of the view that no reasonably possible change in any of the above key assumptions would have an impact on the impairment assessment conclusion.

13. Share capital

	Group and Company			
	30/06/2023		31/12/2022	
	No. of shares		No. of shares	
	'000	\$'000	'000	\$'000
	(Unaudited)	(Unaudited)	(Audited)	(Audited)
Issued and fully paid ordinary shares				
Beginning of period	1,322,554	25,119	1,320,109	24,505
Ordinary shares issued upon vesting of performance shares	1,945 ⁽¹⁾	453	2,445 ⁽²⁾	614
End of period	1,324,499	25,572	1,322,554	25,119

⁽¹⁾ 1,945,210 new ordinary shares were allotted and issued on 13 March 2023 pursuant to the vesting of certain performance shares awarded in March 2020.

⁽²⁾ A total of 2,445,208 new ordinary shares were allotted and issued during the financial year ended 31 December 2022 as a result of the following:

- 1,945,209 new ordinary shares allotted and issued on 14 March 2022 pursuant to the vesting of certain performance shares awarded in March 2020; and
- 499,999 new ordinary shares allotted and issued on 17 October 2022 pursuant to the vesting of certain performance shares awarded in October 2021.

There were no sales, transfers, cancellation and/or use of treasury shares nor subsidiary holdings during 1H 2023. As at 30 June 2023 and 30 June 2022, there were no treasury shares held by the Company and there were no subsidiary holdings.

14. Investment securities held for sale

	Group and Company	
	30/06/2023	31/12/2022
	\$'000	\$'000
	(Unaudited)	(Audited)
At beginning of the period	653	–
Classification as asset held for sale	–	1,093
Less: Impairment loss	(139)	(440)
At end of the period	514	653

During the financial year ended 31 December 2022, the Company decided to divest its investment securities which have accordingly been classified as investment securities held for sale as at 31 December 2022. Non-current assets are classified as held for sale if their carrying amounts will be recovered through a sale transaction.

During 1H 2023, the Company recorded an impairment loss of \$139,000 (2022: \$440,000) in marking down the carrying amount of the investment securities held for sale to its net realisable value of approximately \$514,000 (2022: \$653,000).

15. Investment property

During the financial year ended 31 December 2022, the Company completed the purchase of a commercial property located at 100 Pasir Panjang Road, #04-02, Singapore 118518.

At the Company level, the property is accounted for as an investment property in accordance with SFRS(I) 1-40 *Investment Property* as it is owned by the Company to earn rental income from its subsidiary and/or for capital appreciation. At the Group level, the property is accounted for as an item of property, plant and equipment (“PPE”) in accordance with SFRS(I) 1-16 *Property, Plant and Equipment* as it is used in the Group’s operations.

The property is initially measured at cost, including transaction costs. Subsequent to initial recognition, the property is measured at cost less accumulated depreciation and accumulated impairment loss.

Depreciation of the property begins when it is available for use and is computed on a straight-line basis over the estimated useful life of 30 years.

The Company has entered into an operating lease on the property with a subsidiary for a tenure of 6 years. Rental income recognised by the Company during 1H 2023 is \$75,000 (1H 2022: \$Nil).

Set out below are the carrying amount of the investment property and the movements during 1H 2023 and the financial year ended 31 December 2022:

	Company	
	30/06/2023	31/12/2022
	\$'000	\$'000
	(Unaudited)	(Audited)
Cost		
At beginning of the period	4,012	–
Addition	–	4,012
At end of the period	4,012	4,012
Accumulated depreciation		
At beginning of the period	5	–
Depreciation charge for the period	71	5
At end of the period	76	5
Net book value		
At end of the period	3,936	4,007

The property held by the Company and the Group is as follows:

Description	Location	Tenure
Light industrial property	100 Pasir Panjang, #04-02, Singapore 118518	Freehold

As at 31 December 2022, the fair value of the investment property was approximately \$4,012,000 which was estimated based on its purchase price and transaction costs. As at 30 June 2023, management evaluated and determined that there were no changes to its fair value since the date of acquisition based on the price of recent sales transactions.

As at 30 June 2023, the property had not been pledged to any financial institution to secure bank facilities.

16. Investment in joint ventures

	Group	
	30/06/2023 \$'000 (Unaudited)	31/12/2022 \$'000 (Audited)
Equity shares, at cost	4,871	4,871
Discount on interest-free loan to joint venture	98	98
Share of results of joint ventures	(3,967)	(2,982)
Foreign currency translation	(201)	(201)
	801	1,786

As at 30 June 2023, the Group's cost of investment in joint ventures amounted to \$4,871,000 (2022: \$4,871,000).

Impairment test for loan to a joint venture

	Carrying amount		Basis on which recoverable amount is determined	Post-tax discount rate per annum	
	30/06/2023 \$'000 (Unaudited)	31/12/2022 \$'000 (Audited)		30/06/2023	31/12/2022
Group					
<i>Sino-Singapore Hospital Management (Chongqing) Co., Ltd. ("SSHM")</i>					
Loan to a joint venture	—	306	Value-in-use	18.3%	18.3%

During the financial year ended 31 December 2022, the Group through its subsidiary, TalkMed Chongqing Pte. Ltd., granted an interest-free loan of \$600,000 to its joint venture, SSHM.

As SSHM is an investment holding company with no trade activity, the recoverable amount of the loan to a joint venture has been determined based on value-in-use calculation using cash flow projections from financial budgets of Sino-Singapore Cancer Centre that were approved by management covering a five-year period. The cash flows for the five-year period included revenue growth rate of between 8% and 79% (2022: 8% and 79%).

As a result of the continued difficulties faced by SSHM in the environment that it operates in, the Group had assessed the recoverability of the loan made to it and concluded that a further impairment was required on the loan to the joint venture. Accordingly, an impairment loss of \$315,000 was recorded in 1H 2023 (2022: \$200,000). The impairment loss represented the shortfall between the estimated recoverable amount and the carrying amount of the Group's loan to SSHM.

Key assumptions used in the value-in-use calculations

Growth rates – The forecasted growth rates are based on published industry research and are comparable to the average growth rate for the industry relevant to the entity.

Post-tax discount rate – Discount rate represents the current market assessment of the risks specific to the entity, regarding the time value of money and individual risks of the underlying assets which have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Group and derived from its weighted average cost of capital.

16. Investment in joint ventures (cont'd)

Impairment test for loan to a joint venture (cont'd)

Summary of sensitivity to changes in assumptions

Management is of the view that no reasonably possible change in any of the above key assumptions would have an impact on the impairment assessment conclusion.

17. Subsequent events

There are no known subsequent events which have led to adjustments to this set of condensed interim financial statements.

OTHER INFORMATION REQUIRED BY LISTING RULE APPENDIX 7.2

1. Review

The condensed consolidated statement of financial position of TalkMed Group Limited and its subsidiaries (collectively, the “**Group**”) as at 30 June 2023 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended and certain explanatory notes have not been audited or reviewed.

2. Review of performance of the Group

Performance Review

Revenue

The Group’s revenue for 1H 2023 was \$37.80 million, an increase of \$5.33 million or 16.4% from \$32.47 million in 1H 2022. This was because there were no travel restrictions in Singapore during 1H 2023 while travel restrictions were in place until April 2022 for 1H 2022.

Revenue derived from our 60%-owned subsidiary, CellVec, for cellular and gene therapy related products and services during 1H 2023 amounted to \$0.32 million. This was a decrease of \$0.89 million or 73.8% over the revenue of \$1.21 million in 1H 2022.

Other items of income

Interest income

Interest income increased by \$0.84 million or 569.6% from \$0.15 million in 1H 2022 to \$0.99 million in 1H 2023. The increase was mainly due to higher interest rates for fixed deposits placed in 1H 2023.

Other income

The Group’s other income comprised government-paid childcare and maternity leave, government grant under Special Employment Credit, Wage Credit Scheme, CPF Transition Credit and Jobs Growth Incentive as well as Enterprise Development Grant.

Other income decreased by approximately \$0.07 million or 41.8% from \$0.18 million in 1H 2022 to \$0.10 million in 1H 2023. The decrease was mainly due to the decrease in grant received under Jobs Growth Incentive in 1H 2023.

Other items of expense

Employee benefits expense

Employee benefits expense comprised remuneration paid to doctors, nurses as well as other support staff. These included salaries and wages, allowances, CPF contributions, bonuses and staff benefits.

Employee benefits increased by \$1.96 million or 14.6% from \$13.36 million in 1H 2022 to \$15.32 million in 1H 2023. The increase was mainly due to higher bonus provision and increase in staff salaries.

Performance Review (cont'd)

Other items of expense (cont'd)

Share-based payments expense

Share-based payments to employees related mainly to:

- Options that were granted on 10 May 2019 under the Company's employee share option scheme;
- Performance shares that were granted on 13 March 2020, 15 October 2021 and 18 October 2022 under the Company's performance share plan; and
- Performance shares that were granted on 25 April 2021 under a subsidiary's performance share plan.

It increased by \$0.01 million or 5.0% from \$0.26 million in 1H 2022 to \$0.27 million in 1H 2023. The increase was mainly due to the new performance shares granted on 18 October 2022, partially offset by the decrease in number of options left to be vested under the Company's employee share option scheme in 1H 2023 as compared to 1H 2022.

Depreciation of right-of-use assets

The Group recorded depreciation of right-of-use assets of \$1.05 million in 1H 2023, an increase of \$0.04 million or 3.8% from \$1.01 million in 1H 2022.

Depreciation of property, plant and equipment

Depreciation of property, plant and equipment increased by \$0.05 million or 18.7% from \$0.27 million in 1H 2022 to \$0.32 million in 1H 2023. The increase was mainly due to the depreciation expense incurred in 1H 2023 for the property purchased in December 2022.

Finance costs

Finance costs mainly related to unwinding of discount adjustment of loan to a subsidiary and lease liabilities. Finance costs decreased by approximately \$0.03 million or 13.7% from \$0.18 million in 1H 2022 to \$0.16 million in 1H 2023 mainly due to the decrease in finance costs on lease liabilities.

Other operating expenses

Other operating expenses comprised mainly professional and consultancy fees, directors' fees, donation made, advertising and marketing expenses, utilities expenses, repair and maintenance costs as well as laboratory consumables and services fees.

Other operating expenses increased by approximately \$1.68 million or 76.3% from \$2.20 million in 1H 2022 to \$3.87 million in 1H 2023. This increase was due to higher expenses, such as overseas travelling expenses, repair and maintenance expenses and laboratory consumable and services fees, incurred by the Group.

Performance Review (cont'd)

Other items of expense (cont'd)

Impairment loss

As a result of the continued difficulties faced by our joint venture, Sino-Singapore Hospital Management (Chongqing) Co., Ltd. in the environment that it operates in, the Group had assessed the recoverability of the loan made to it and concluded that a further impairment was required on the loan to the joint venture. Accordingly, an impairment loss of approximately \$0.32 million was recorded in 1H 2023.

During the financial year ended 31 December 2022, the Company decided to divest its investment securities which have accordingly been classified as investment securities held for sale as at 31 December 2022. During 1H 2023, the Company recorded an impairment loss of approximately \$0.14 million in marking down the carrying amount of the investment securities held for sale to its net realisable value of approximately \$0.51 million.

Share of results of associate

The Group's share of loss after tax of its associate, Hong Kong Integrated Oncology Centre Holdings Limited, was \$0.02 million in 1H 2023. This was a decrease of \$0.06 million or 76.9% as compared to \$0.08 million in 1H 2022.

Share of results of joint ventures

The Group's share of loss after tax of its joint ventures, Sino-Singapore Hospital Management (Chongqing) Co., Ltd. and Chongqing Medtech Health Management Co., Ltd., was \$0.99 million in 1H 2023. This was an increase of approximately \$0.19 million or 24.5% as compared to \$0.79 million in 1H 2022.

Income tax expense

Income tax expense increased by approximately \$0.76 million or 23.9% from \$3.17 million in 1H 2022 to \$3.92 million in 1H 2023 due to higher profits of its subsidiary, SCC, in 1H 2023. The effective tax rate for 1H 2023 was 23.9% as compared to 21.7% in 1H 2022.

Profit after tax

The Group recorded profit after tax of \$12.49 million in 1H 2023 as compared to \$11.45 million in 1H 2022, an increase of \$1.04 million or 9.1%. The reasons for the increase have been discussed above.

Review of the Group's Financial Position

Non-current assets

The Group's non-current assets comprised property, plant and equipment, right-of-use assets, investment in joint ventures, investment in associate, loan to a joint venture and trade receivables. Non-current assets decreased by approximately \$1.04 million which was attributable to the following:

- Decrease in the carrying amount of investment in joint ventures of \$0.99 million which arose from the share of loss for 1H 2023;
- Decrease in the carrying amount of investment in associate of \$0.02 million which arose from the share of loss for 1H 2023; and
- Decrease in the carrying amount of a loan to joint venture of \$0.31 million which arose due to the impairment of loan in 1H 2023.

These were partially offset by the following:

- Increase in the carrying amount of property, plant and equipment of \$0.09 million;
- Increase in right-of-use assets of \$0.10 million; and
- Increase in trade receivables of \$0.08 million.

Current assets

Current assets comprised inventories, investment securities held for sale, prepaid operating expenses, trade and other receivables and cash and short-term deposits. Current assets decreased by \$2.35 million which was attributable to the following:

- Decrease in inventories of \$0.07 million;
- Decrease in investment securities held for sale of \$0.14 million;
- Decrease in trade and other receivables of \$2.50 million; and
- Decrease in prepaid operating expenses of \$0.13 million.

These were partially offset by the increase in cash and short-term deposits of \$0.49 million.

The decrease in trade and other receivables was mainly attributable to the lower outstanding balances from trade debtors.

Current liabilities

Current liabilities comprised trade and other payables, other liabilities, lease liabilities and income tax payable. Current liabilities increased by approximately \$3.64 million which was attributable to the following:

- Increase in trade and other payables of \$1.67 million mainly due to higher trade payables and GST payable;
- Increase in other liabilities of \$1.95 million mainly due to the increase in deferred revenue; and
- Increase in lease liabilities of \$0.03 million.

Non-current liabilities

Non-current liabilities comprised lease liabilities and loan from non-controlling shareholder to a subsidiary. Non-current liabilities increased by \$0.13 million mainly due to the increase in lease liabilities of \$0.07 million and the increase in loan from non-controlling shareholder to a subsidiary of \$0.06 million (due to the unwinding of discount adjustment of loan from non-controlling shareholder to a subsidiary).

Review of the Group's Financial Position (cont'd)

Equity attributable to owners of the Company

The decrease was mainly attributable to the final dividends paid to shareholders in respect of the financial year ended 31 December 2022, partially offset by the profits earned during the period.

Non-controlling interests

This related to the 40% non-controlling interests' share in the net equity of CellVec as well as the share-based payments (arising from the award of performance shares) of its subsidiary, TalkMed China Pte. Ltd..

Review of the Group's Cash Flows

Operating activities

Net cash flows from operating activities amounted to approximately \$21.87 million. This comprised operating cash flows before changes in working capital of \$18.67 million, net changes in working capital of \$6.24 million and interest received of \$0.98 million, less interest paid on lease liabilities of \$0.10 million and income tax paid of \$3.93 million.

The net decrease in working capital of \$6.24 million was mainly due to the following:

- Decrease in inventories of \$0.07 million;
- Decrease in trade and other receivables of \$2.42 million;
- Decrease in prepaid operating expenses of \$0.13 million;
- Increase in trade and other payables of \$1.67 million; and
- Increase in other liabilities of \$1.95 million.

Investing activities

Net cash flows used in investing activities of \$0.45 million was mainly attributable to the purchase of property, plant and equipment by CellVec.

Financing activities

Net cash flows used in financing activities amounted to \$20.93 million. This was attributable to the payment of final dividends of \$19.87 million to shareholders in respect of the financial year ended 31 December 2022 and the payment for principal portion of lease liabilities of \$1.06 million.

Net increase in cash and cash equivalents

The reasons for the net increase in cash and cash equivalents of \$0.49 million for 1H 2023 have been discussed above. Cash and cash equivalents totalled \$81.07 million as at 30 June 2023.

3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months.

Singapore

While our oncology business saw an improvement in the patient numbers from the region following the easing of community and border measures by the government at the end of March 2022, we have yet to revert to pre-pandemic levels. We face challenges from growing competition in the region as a result of a strong Singapore dollar relative to the currencies in the region and investments to build up healthcare infrastructure and expertise in the region. Nevertheless, we expect our foreign patient numbers in 2023 to be comparable to 2022 as connectivity and traffic between Singapore and the region continues to be restored to pre-COVID-19 levels. According to Changi Airport' Group's press release dated 20 July 2023 "Operating indicators for Q2 2023", passenger movements had not been fully restored to pre-COVID-19 levels and any further increase could potentially provide an uplift to our foreign patient numbers.

As part of the government's effort to keep cancer treatments and insurance premiums affordable in the longer term, the Ministry of Health introduced a Cancer Drug List ("CDL") in September 2022 where only treatments on the CDL may be claimed under the Medishield Life, MediSave and Integrated Shield Plans.

Following the introduction of CDL, our local patient numbers during 1H 2023 were adversely affected as patients had to bear higher out-of-pocket payments with the change in the coverage by the insurance companies for cancer treatments. We expect the local patient numbers to be soft for the rest of the year but we will continue to pursue the growth in foreign patients to counter the headwinds that we have experienced in our local patient segment.

Over the last 12 months, CellVec has successfully delivered batches of lentiviral vectors that are compliant with current good manufacturing practice (CGMP) regulations to clients ranging from small biotech companies to research powerhouses. This was made possible by industrialising its manufacturing process, bringing in controls and streamlining processes.

CellVec is now better positioned to take on a diverse range of clients in the next 12 months. With an expected pick-up in venture funding in the cell and gene therapy sector during the second half of 2023, we hope to capitalise on the market growth by closing in on active customer leads which include, among others, biotechnology companies, research institutes to large pharmaceutical companies.

Hong Kong/ China

As Hong Kong and mainland China returned to normalcy following the roll-back of COVID-19 measures during the earlier part of 2023, we have seen an improvement in our patient numbers at our centres, thereby lifting their financial performances modestly during 1H 2023.

We aim to continue to grow our patient numbers by raising the profiles of our centres through collaborations with established hospitals and insurance companies, hiring of more experienced doctors and other medical professionals as well as looking into new services to distinguish our centres from their competitors. Also, with the resumption of the 15-day VISA-free entry for Singaporeans into China on 26 July 2023, we will work on increasing the frequency of visits to our China centres by our Singapore experts which is expected to further bolster the growth in caseloads at these centres.

5. Dividend information

(a) Any dividend declared or recommended for the current financial period reported on

Yes, the Board has declared an interim cash dividend in respect of the financial year ending 31 December 2023 as follows:

Name of dividend	Interim dividend
Dividend type	Cash
Dividend rate	\$0.009 per ordinary share
Tax rate	Tax exempt (one-tier)

(b) Any dividend declared for the corresponding period of the immediately preceding financial year

Yes.

Name of dividend	Interim dividend
Dividend type	Cash
Dividend rate	\$0.015 per ordinary share
Tax rate	Tax exempt (one-tier)

(c) The date the dividend is payable

Dividend will be paid on 22 August 2023.

(d) The date on which Registrable Transfers received by the Company (up to 5.00 pm) will be registered before entitlements to the dividend are determined.

The Share Transfer Books and Register of Members of the Company will be closed at 5:00 p.m. on 15 August 2023 for the purpose of determining entitlements of ordinary shareholders to the tax exempt (one-tier) interim dividend in respect of the financial year ending 31 December 2023.

6. If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

Not applicable.

7. If the Group has obtained a general mandate from the shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group does not have a general mandate from its shareholders for Interested Person Transactions pursuant to Rule 920(1)(a)(ii).

8. Confirmation pursuant to Rule 720(1)

TalkMed Group Limited confirms that undertakings under Rule 720(1) have been obtained from all directors and executive officers in the format set out in form Appendix 7.7.

9. Confirmation pursuant to Rule 705(5)

The Board of Directors of the Company hereby confirms that to the best of their knowledge, nothing has come to their attention which may render the unaudited interim financial statements of the Group and the Company for 1H 2023 to be false or misleading in any material aspect.

BY ORDER OF THE BOARD

Ang Peng Tiam
Chief Executive Officer
7 August 2023